TeamDrive
RUS

Bacterias hibernation and eating habits spark new ideas for tackling resistant infections

28 September 2018

Arlene Weintraub / FiercePharma

To effectively combat stubborn infections, drug developers need to better understand why bacteria are able to evade destruction with antibiotics. One team at the University of Copenhagen has discovered a surprising talent that some bacteria have that allows them to resist antibiotic attacks: hibernation. It's one of two recent discoveries that could spark new ideas for developing medicines to treat resistant infections.

The University of Copenhagen researchers discovered that some pathogenic bacteria enter a dormant state, much like hibernation, in the presence of antibiotics. When the antibiotics are gone, the bugs wake up and return to business as usual. The team published the finding in the journal Science Signaling.

The researchers started by studying E. coli samples from urinary tract infections that had initially responded to antibiotics.

“In time, the bacteria re-awoke and began to spread once again," said Kenn Gerdes, professor of biology at the University of Copenhagen, in a statement.

Gerdes’ team studied exactly what was happening in the cells that went dormant, and they found an enzyme that they believe put the bacteria in the hibernation-like state.

Separately, a team led by the University of Washington School of Medicine and the University of Nebraska Medical Center figured out another quirk some bacteria have that might also be able to be applied to drug development. Pseudomonas aeruginosa, which causes infections in the urinary tract and other sites, can be tricked into absorbing gallium, because the bacteria mistake the metal for nutritious food. The gallium disrupts the ability of the bacteria to multiply, the researchers reported in the journal Science Translational Medicine.

Gallium can fool bacteria because it looks much like iron, a nutrient that helps the bugs multiply and drive infection. "This and other essential processes require iron, and gallium is a monkey wrench that shuts the system down," said co-author Bradley Britigan, professor of internal medicine at the University of Nebraska Medical Center, in a statement.

They went on to test a single dose of gallium in mice and found that it cured lung infections caused by Pseudomonas aeruginosa. Bacteria can slowly develop resistance to bacteria, but when the researchers combined the metal with existing antibiotics, they found the potency of the attack increased.

They went on to test gallium in 20 people with cystic fibrosis, a disease marked by hard-to-fight lung infections. They reported that the dose tested was safe and that they saw an improvement in the patients’ lung function.

Disrupting the process by which bacteria obtain and use nutrients is not a new idea, but developing treatments to accomplish that feat has proven challenging. The authors noted in their study that their preliminary findings would need to be confirmed in a larger, placebo-controlled study, but that they’re encouraged by the prospect of using gallium to fight infections.

“Our proof-of-principle work with P. aeruginosa and the fact that gallium has broad-spectrum activity against many extracellular and intracellular pathogens raise the possibility that gallium or other iron-disrupting strategies may be useful in infections caused by a range of resistant organisms,” they wrote.

"The enzyme triggers a 'survival program' that almost all disease-causing bacteria deploy to survive in the wild and resist antibiotics in the body,” Gerdes said, adding that developing an antibiotic to target that mechanism could prove useful in fighting resistant infections.

Source


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more